Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Annexon revenue
Annexon's revenue is $284,900.
What is Annexon's revenue?
- Annexon has 46 employees, and the revenue per employee ratio is $6,193.
- Annexon peak revenue was $284.9K in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Annexon financial information
| CEO | Douglas Love |
| Industry | Commercial & Professional Services |
| Company Type | Public |
| Employees Number | 46 |
| Date Founded | 2011 |
| Headquarters | South San Francisco, California |
| Number of Locations | 1 |
| Revenue | $284.9K |
| Net Income | -$141,947,000 |
| Tax Rate | -0.0% |
| Total Assets | $285,096,000 |
| Ticker | ANNX |
Annexon jobs you might like
Annexon financing
Annexon received early financing of $1000.0K on 2011-08-22.
| Series | Round size | Date |
|---|---|---|
| Seed | $1M | 08/2011 |
| Series A | $34M | 12/2014 |
| Series B | $44M | 06/2016 |
| Series C | $75M | 12/2018 |
| Series C | $100M | 07/2020 |
Annexon investors
| Investors | Security type |
|---|---|
| Novartis Venture Fund | Series A |
| SATTER INVESTMENT MANAGEMENT | Series A |
| The Blackstone Group Inc | Series A |
| Novartis Venture Fund | Series B |
| SATTER INVESTMENT MANAGEMENT | Series B |
| New Enterprise Associates (NEA) | Series B |
| Correlation Ventures | Series B |
| The Blackstone Group Inc | Series B |
| Novartis Venture Fund | Series C |
| SATTER INVESTMENT MANAGEMENT | Series C |
| Bain Capital Life Sciences | Series C |
| New Enterprise Associates (NEA) | Series C |
| Adage Capital Management | Series C |
| Blackstone Technology Group | Series C |
| Surveyor Capital | Series C |
| Eventide Asset Management | Series C |
| Logos Capital | Series C |
| Bain Capital Life Sciences | Series C |
| New Enterprise Associates (NEA) | Series C |
| Deerfield | Series C |
| Adage Capital Management | Series C |
| Farallon Capital Management | Series C |
| BlackRock, Inc. | Series C |
| Surveyor Capital | Series C |
| Redmile Group | Series C |
| SATTER INVESTMENT MANAGEMENT | Series C |
| Blackstone Life Sciences | Series C |
| Janus Henderson Investors | Series C |
| Deerfield | Series C |
Annexon competitors
Annexon's top competitor, XORTX Therapeutics, earned an annual revenue of $6.2B.
Annexon's smallest competitor is Akari Therapeutics with revenue of $1.6M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| TG Therapeutics | - | $329.0M | 286 | - |
| XORTX Therapeutics | - | $6.2B | 2 | - |
| Apexigen | - | $4.9M | 39 | - |
| Alzheon | - | $8.0M | 5 | - |
| Pandion Therapeutics | - | $8.8M | 43 | - |
| Prevail Therapeutics | - | $74.3M | 66 | - |
| Akari Therapeutics | - | $1.6M | 8 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Annexon, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Annexon. The employee data is based on information from people who have self-reported their past or current employments at Annexon. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Annexon. The data presented on this page does not represent the view of Annexon and its employees or that of Zippia.
Annexon may also be known as or be related to ANNEXON, INC., Annexon, Annexon Inc. and Annexon, Inc.